| Janet M Hummer, MD | |
|
9202 N Meridian St Ste 100, Indianapolis, IN 46260-1810 | |
| (317) 841-2020 | |
| (317) 570-7433 |
| Full Name | Janet M Hummer |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 33 Years |
| Location | 9202 N Meridian St Ste 100, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336180181 | NPI | - | NPPES |
| 200231440 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 0105776A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Surgeons Of Indiana, Pc | 0446267876 | 18 |
News Archive
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
STERIPLEX® Health Care (HC) is a new Sterilant/Sporicide, Tuberculocide, and Bactericide, which has recently received Federal EPA Registration. STERIPLEX® HC sets new standards, killing MRSA, spores and other pathogens in a fraction of the time of competing products while remaining safe to people and the environment.
› Verified 2 days ago
| Entity Name | Eye Surgeons Of Indiana, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457399834 PECOS PAC ID: 0446267876 Enrollment ID: O20060309000629 |
News Archive
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
STERIPLEX® Health Care (HC) is a new Sterilant/Sporicide, Tuberculocide, and Bactericide, which has recently received Federal EPA Registration. STERIPLEX® HC sets new standards, killing MRSA, spores and other pathogens in a fraction of the time of competing products while remaining safe to people and the environment.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janet M Hummer, MD 9202 N Meridian St Ste 100, Indianapolis, IN 46260-1810 Ph: (317) 841-2020 | Janet M Hummer, MD 9202 N Meridian St Ste 100, Indianapolis, IN 46260-1810 Ph: (317) 841-2020 |
News Archive
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
STERIPLEX® Health Care (HC) is a new Sterilant/Sporicide, Tuberculocide, and Bactericide, which has recently received Federal EPA Registration. STERIPLEX® HC sets new standards, killing MRSA, spores and other pathogens in a fraction of the time of competing products while remaining safe to people and the environment.
› Verified 2 days ago
Dr. Frank N. Hrisomalos, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10300 N Illinois St Ste 1070, Indianapolis, IN 46290 Phone: 317-817-1500 Fax: 317-817-1511 | |
Dr. Sang Hoon Kim, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9002 N Meridian St, Suite 102, Indianapolis, IN 46260 Phone: 317-573-4410 Fax: 317-573-4412 | |
Dr. David V Poer, M.D., F.A.C.S. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 8902 N Meridian St, Ste 120, Indianapolis, IN 46260 Phone: 317-582-1118 Fax: 317-582-1116 | |
Scott Hobson, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 10300 N Illinois St, Suite 2020, Indianapolis, IN 46290 Phone: 317-817-1976 Fax: 317-817-1737 | |
John Thomas Minturn, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10300 N Illinois St, Suite #1030, Indianapolis, IN 46290 Phone: 317-817-1586 Fax: 317-817-1399 | |
Amir Reza Hajrasouliha, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1160 W Michigan St, Indianapolis, IN 46202 Phone: 317-944-2020 | |
Keith R Knuth, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 901 E 86th St, Indianapolis, IN 46240 Phone: 317-844-5500 Fax: 317-573-4230 |